Examining the effects of magnesium replacement in hospitalized patients with low magnesium levels
Official title: Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards
Run by HaEmek Medical Center, Israel · NCT03088852 · Data updated 2026-11-12
This study is testing if giving magnesium supplements to hospitalized patients with low magnesium levels can help them recover better and stay in the hospital for a shorter time.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 330 (estimated) |
| Sponsor | HaEmek Medical Center, Israel Academic / other |
| Locations | 1 site (Afula) |
| Status | Recruiting |
| Started | May 10, 2017 |
| Main results expected | December 2025 |
| Study ends | December 2026 |
| Registry record updated | March 18, 2025 |
| Trial ID | NCT03088852 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are hospitalized patients over 18 years old with hypomagnesemia who can provide consent.
✕Probably not a fit
Patients who are critically ill, on dialysis, or have severe malnutrition may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the impact of magnesium replacement therapy on patients hospitalized with hypomagnesemia, a condition characterized by low magnesium levels. It aims to determine whether administering magnesium citrate can improve patient outcomes, including mortality rates and length of hospital stay. The study will involve patients over 18 years old who have been diagnosed with hypomagnesemia and are able to provide consent. The intervention consists of giving magnesium citrate for several months to replenish magnesium stores.
Why it matters
Potential benefit: If successful, this study could lead to improved recovery and reduced mortality for patients with low magnesium levels.
How similar studies have gone: Previous studies have indicated that magnesium deficiency is linked to poor outcomes, but this specific approach to treatment is less commonly tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent. Exclusion Criteria: * A patient unable to give consent. * A patient admitted for an elective procedure. * A patient in critical condition or dying. * Patients with advanced kidney disease with eGFR\<15ml/min or on dialysis. * Patients with severe diarrhea, precluding use of magnesium citrate. * Patients already receiving magnesium supplements. * Patients with severe malnutrition or life-threatening hypomagnesemia (serum level \<1mg/dL), requiring intravenous and oral replacement of magnesium.
Where it's running
-
Emek Medical Center
Afula, Israel Recruiting
Study contacts
- Principal investigator: Frieda Wolf — haemek medical center
- Study coordinator: Frieda Wolf
- Email: friedawo@clalit.org.il
- Phone: 972-4-6495476
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Urine extracellular vesicle biomarkers for people with low magnesium
We will test whether tiny particles in urine can reveal the kidney-related causes of low blood magnesium in adults with hypomagnesemia.
-
National Registry for Rare Kidney Diseases
This study is collecting health information from people with rare kidney diseases to help improve treatments and create better care guidelines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.